Researchers from Humana Healthcare Research and University of Chicago Medicine found that Medicare Advantage members with COPD and low medication adherence significantly improved their ...
Medicare Part D and Medicare Advantage (Part C) plans with drug coverage typically cover inhalers for COPD. But you may still be responsible for a portion of the cost. If you have chronic obstructive ...
There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Leah J. Witt, MD: Hello. I'm Dr Leah Witt. Welcome to season one of Medscape InDiscussion, chronic obstructive pulmonary disease (COPD) podcast series. Today we're talking medications, especially ...
A new study published in the Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation shows how an innovative phone-based inhaler education program helped Medicare Advantage ...
Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...
Researchers explained that educational level, duration of disease, and inhaler type may affect adherence in patients with chronic obstructive pulmonary disease (COPD). Most patients with chronic ...
Umeclidinium-Vilanterol Inhaler May Reduce COPD Exacerbations Compared With Other LAMA-LABA Inhalers
Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...
Various types of inhalers, including short- and long-lasting options, are available for managing chronic obstructive pulmonary disease (COPD). A person can get a COPD inhaler through Medicare Part D ...
Metered-dose inhaler propellants have contributed a rising amount to greenhouse gases in the U.S. Emissions per inhaler declined slightly over the past decade, but an increase in annual prescription ...
New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly ...
Clinical Trials Arena on MSN
AstraZeneca’s COPD drug gains third Phase III win
Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results